{"id":"W4306743619","doi":"10.1111/bjh.18519","title":"<scp>Real‐world</scp> experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The <scp>SCHOLAR</scp>‐2 retrospective chart review study","year":2022,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"MD Precision (Canada); Precision Nanosystems (Canada)","funders":"National Cancer Institute; Allergan; Incyte; Genentech; Sunesis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; National Cancer Research Institute; Gilead Sciences; Sanofi; Amgen; Pfizer; MorphoSys; Celgene; BeiGene; Patient-Centered Outcomes Research Institute","keywords":"Mantle cell lymphoma; Medicine; Bruton's tyrosine kinase; Refractory (planetary science); Chart; Cancer research; Ibrutinib; Tyrosine kinase; Internal medicine; Lymphoma; Oncology; Leukemia; Biology; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009479283,0.0001560029,0.0003126617,0.001585082,0.0004191425,0.001086907,0.0003831079,0.000302011,0.0007987462],"category_scores_gemma":[0.002581722,0.0001971352,0.0003384373,0.002294011,0.0004850746,0.0005841882,0.0006684592,0.0002834047,0.0001783521],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009178043,"about_ca_system_score_gemma":0.001079114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009180777,"about_ca_topic_score_gemma":0.01015174,"domain_scores_codex":[0.9989154,0.000302557,0.0002051898,0.0002437802,0.0002125152,0.0001205568],"domain_scores_gemma":[0.9946699,0.0008424734,0.003252496,0.000260649,0.000556333,0.0004181606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00007088624,0.00002724698,0.9955873,0.00005627858,0.00004506316,0.0006099147,0.000396431,0.00003579929,0.0001583658,0.0000294641,0.0003973508,0.002585929],"study_design_scores_gemma":[0.00001683187,0.0001396685,0.9943141,0.00004017487,0.00004018303,0.00249327,0.0009902311,0.00008809503,0.0002243927,0.00001493803,0.001626538,0.00001160504],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969536,0.0007135156,0.0000892665,0.00005171061,0.000004213943,0.00003053053,0.001528759,0.000007067229,0.0006214305],"genre_scores_gemma":[0.9974926,0.0005430712,0.0001211364,0.00005796478,0.00001149837,0.0000192313,0.001618705,0.000004973066,0.0001308598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009180777,"threshold_uncertainty_score":0.0182547,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006174186714432873,"score_gpt":0.2268818697572513,"score_spread":0.2207076830428185,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}